Effectiveness of varicella vaccines as postexposure prophylaxis

Pediatric Infectious Disease Journal

Volumn 29, Issue 1, 2010, Pages 10-13

  Brotons, Maria ^a   Campins, Magda ^a   Méndez, Leonardo ^a   Juste, Concepción ^b   Rodrigo, Jose Ángel ^a   Martínez, Xavier ^a   Hermosilla, Eduardo ^a   Pinós, Laia ^a   Vaqué, Josep ^a  

^a Escuela Universitaria de Enfermeria   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Chickenpox; Effectiveness; Postexposure prophylaxis; Prevention; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ARTICLE; CHICKENPOX; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TELEPHONE; TREATMENT OUTCOME; VACCINATION;

EID: 74049091820     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b36022     Document Type: Article

References (32)

1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361-381.
2. Guess HA, Broughton DD, Melton LJ III, et al. Population-based studies of varicella complications. Pediatrics. 1986;78(4 pt 2):723-727.
3. Meyer PA, Seward JF, Jumaan AO, et al. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000;182: 383-390.
4. Gil A, Gonzalez A, Oyaguez I, et al. The burden of severe varicella in Spain, 1995-2000 period. Eur J Epidemiol. 2004;19:699-702.
5. Pachón I, Á lvarez E. Varicela: incidencia y estacionalidad en el sistema de notificación español. Vacunas. 2001;2(suppl 1):5-11.
6. Pachón I, Amela C, de Ory F, et al. Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Bol Epidemiol Semanal. 1998;6:93-100.
7. Salleras L, Dominguez A, Vidal J, et al. Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine. 2000;19:183-188.
8. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48: 1-5
9. American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics. 2000;105(1 pt 1):136-141.
10. Ferson MJ. Varicella vaccine in post-exposure prophylaxis. Commun Dis Intell. 2001;25:13-15.
11. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986;78(4 pt 2):748-756.
12. Asano Y, Nakayama H, Yazaki T, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics. 1977;59:3-7.
13. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;2:1288-1290.
14. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J. 1998;17:256-257.
15. Gentile A, Marcó J, Martínez E, et al. Efectividad de la vacuna anti-varicela-zoster como profilaxis post-exposición. Arch Argent Pediatr. 2002; 100:25-30.
16. Mor M, Harel L, Kahan E, et al. Efficacy of postexposure immunization with live attenuated varicella vaccine in the household setting-a pilot study. Vaccine. 2004;23:325-328.
17. Watson B, Seward J, Yang A, et al. Postexposure effectiveness of varicella vaccine. Pediatrics. 2000;105(1 pt 1):84-88.
18. American Academy of Pediatrics. Varicella-Zoster Infections. In: Pickering LK, Baker CJ, Long SS, et al, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006: 711-725.
19. Salleras L, Dominguez A. Evaluacion de la eficacia de las vacunas y de la efectividad de los programas de vacunaciones. In: Salleras L, ed. Vacuna-ciones Preventivas. 2nd ed. Barcelona, Spain: Masson; 2003:781-799.
20. Ross AH. Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med. 1962;267:369-376.
21. SPSS 13.0 (for Windows) [computer program]. Version 13.0. Chicago, IL: SPSS, Inc, 2004.
22. Stata/SE 8.2 (for Windows) [computer program]. Version 8.2. College Station, TX: StataCorp LP; 2005.
23. Asano Y, Hirose S, Iwayama S, et al. Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination. Biken J. 1982;25:43-45.
24. Katsushima N, Yazaki N, Sakamoto M. Effect and follow-up study on varicella vaccine. Biken J. 1984;27:51-58.
25. Naganuma Y, Osawa S, Takahashi R. Clinical application of a live varicella vaccine (Oka strain) in a hospital. Biken J. 1984;27:59-61.
26. Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev. 2008:CD001833.
27. Varilrix [Product Information]. Madrid Spain: GlaxoSmithKline. [Agemed web site.] April 2006. Available at: https://sinaem4.agemed.es/consaem/ especialidad.do?metodo=verFichaWordPdf&codigo=61671&formato= pdf&formulario=FICHAS. Accessed September 23, 2008.
28. Varivax (Varicella Virus Vaccine Live) [Product Information]. Madrid Spain: Sanofi Pasteur MSD. [Agemed web site.] February 2005. Available at: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFicha WordPdf&codigo=65709&formato=pdf&formulario=FICHAS. Accessed September 23, 2008.
29. Kavaliotis J, Petridou S, Karabaxoglou D. How reliable is the history of chickenpox? Varicella serology among children up to 14 years of age. Int J Infect Dis. 2003;7:274-277.
30. Lieu TA, Black SB, Takahashi H, et al. Varicella serology among school age children with a negative or uncertain history of chickenpox. Pediatr Infect Dis J. 1998;17:120-125.
31. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984;310:1409-1415.
32. Batalla-Clavell J, Vidal-Tort J, eds. Manual de vacunacions. 4th ed. Barcelona, Spain: Direccio General de Salut Publica; 2006.